Podcast Episodes
Back to Search
Apr 27, 2026 | Sun Pharma just wrote an eleven-point-seven-five billion dollar check to acquire Organon
Sun Pharma just wrote an eleven-point-seven-five billiondollar check to acquire Organon — the largest outbound pharma acquisition in Indian history, …
2 months, 3 weeks ago
Apr 24, 2026 | Foundayo Trails Oral Wegovy 5-to-1 in Week 2; Inhibrx Draws $6.7B
Lilly's Foundayo logs just 3,707 prescriptions in week two vs. 18,410 for Novo's oral Wegovy — a 5:1 gap that sent Lilly stock tumbling. Inhibrx surg…
2 months, 4 weeks ago
Apr 23, 2026 | Regeneron's Otarmeni Approved as First Gene Therapy for Hearing Loss
FDA approves Regeneron's Otarmeni — the first gene therapy for genetic hearing loss — as Regeneron closes the 17th and final White House MFN pricing …
3 months ago
Apr 21, 2026 | Merck Welireg Fails First-Line Kidney Cancer; Lilly's $7B Kelonia CAR-T
Merck's Welireg misses in first-line RCC — Cantor challenges $2B+ peak sales. Lilly buys Kelonia for up to $7B in in vivo CAR-T push. Medicare indefi…
3 months ago
Apr 20, 2026 | Lilly's $7B Kelonia In Vivo CAR-T Bet; TIGIT Fails Again at Gilead-Arcus
Eli Lilly pays $3.25B upfront for Kelonia Therapeutics' invivo CAR-T platform in a deal worth up to $7B — the sixth buyout in this space since March …
3 months ago
Apr 19, 2026 | Allogene's Off-the-Shelf CAR-T Clears Futility Bar; Kailera Prices $625M IPO
Allogene's cema-cel drives MRD negativity in 7 of 12lymphoma patients in Phase 3 Alpha3 — stock surges 50%+. Plus: Kailera's $625M biotech IPO, UCB's…
3 months ago
Apr 16, 2026 | Lilly Foundayo Clears Heart Safety for Diabetes Filing; Cochrane Calls Amyloid Drugs 'Trivial'
Foundayo hits MACE-4 non-inferiority (HR 0.84) as Lillytargets diabetes filing by Q2 — but FDA requests liver risk data. Plus: Cochrane review dismis…
3 months, 1 week ago
Apr 15, 2026 | J&J Q1 Earnings Beat on Tremfya Growth; Revolution Medicines $2B Raise
J&J's Tremfya hits $1.6B in Q1 sales with 74% growth,answering the Stelara biosimilar cliff. Plus: Revolution Medicines prices a $2B offering, Beelin…
3 months, 1 week ago
Apr 14, 2026 | Daraxonrasib Nearly Doubles Pancreatic Cancer Survival; Neurocrine-Soleno $2.9B Deal
Daraxonrasib slashes death risk 60% in metastatic pancreaticcancer Phase 3 — Revolution Medicines leads a $1.5B offering wave. Neurocrine acquires So…
3 months, 1 week ago
Apr 12, 2026 | FDA Rejects Replimune RP1 Again; Sun Pharma's $12B Organon Bid; Amgen TEPEZZA Subcutaneous Win
FDA issues second CRL for Replimune's melanoma therapy RP1 —stock drops 20%, single-arm trial debate sharpens. Sun Pharma's $12B all-cash bid for Org…
3 months, 1 week ago